INOVIO PHARMACEUTICALS INC Inactive Instrument
Inovio Pharmaceuticals Inc Share Price Nyse
Equities
US45773H1023
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 14/05 | Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target | MT |
| 13/05 | Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 480K 40.03M | Sales 2025 * | 8.82M 736M | Capitalization | 296M 24.69B |
|---|---|---|---|---|---|
| Net income 2024 * | -118M -9.85B | Net income 2025 * | -109M -9.1B | EV / Sales 2024 * | 617 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 33.5 x |
| P/E ratio 2024 * |
-2.66
x | P/E ratio 2025 * |
-3.41
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.3% |
More Fundamentals
* Assessed data
More news
Latest transcript on Inovio Pharmaceuticals Inc
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 25/19/25 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 01/02/01 |
| Chief Tech/Sci/R&D Officer | - | 01/07/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 01/03/01 |
Lota Zoth
BRD | Director/Board Member | 64 | 01/18/01 |
Jay Shepard
BRD | Director/Board Member | 65 | 15/20/15 |
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.
Calendar
| 1st Jan change | Capi. | |
|---|---|---|
| +29.03% | 49.18B | |
| -0.10% | 42.11B | |
| +47.13% | 40.37B | |
| -5.26% | 28.85B | |
| +11.48% | 26.09B | |
| -22.74% | 18.71B | |
| +9.06% | 13.26B | |
| +30.01% | 12.32B | |
| -1.51% | 11.99B |
